Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Eli Lilly And Co (LLY) Price & Performance

Enphase Energy IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Eli Lilly And Co — how do they compare? Enphase Energy Inc trades at $42.61 (market cap $5.59B), while Eli Lilly And Co trades at $1,200.75 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 193.2× Enphase Energy Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.

ENPHLLY
Market Cap
$5.59B$1.08T
Sector
TechnologyHealth
52-Week High
$72.33$1.24K
52-Week Low
$26.12$639.43
Enterprise Value
$5.23B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $40.92, down 2.27% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Recent Q2 2026 earnings matched estimates but revenue declined 19.6% year-over-year, reflecting ongoing challenges in U.S. residential demand. The company is expanding its battery and commercial segments, with new product launches like the IQ Battery 10C aiming to drive recovery. Analyst consensus is a 'Buy' with a $45.37 price target, implying potential upside from current levels.

Outlook remains cautious but opportunistic; ENPH's valuation multiples are elevated (P/E 41.88, P/S 4.25), requiring earnings normalization for sustained gains. Key risks include cyclical solar demand, interest rate sensitivity, and competitive pressures. Near-term catalysts hinge on execution in storage and international markets, with the stock offering leverage to a sector rebound if execution improves.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY